Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy. 1998

A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
Information Network of Departments of Dermatology (IVDK), University of Göttingen, Germany.

We investigated whether patients with contact allergy differed from non-contact-allergic, non-atopic controls with regard to genotype and phenotype of the polymorphic enzyme N-acetyltransferase 2 (NAT2). 55 contact-allergic patients recruited from the Information Network of Departments of Dermatology (IVDK) were compared to 85 controls from among local health care personnel. NAT2 activity was calculated from HPLC analysis of the ratio of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 1-methylxanthine (1MX) in the urine. NAT2 genotype was determined by polymerase chain reaction (PCR). A statistically significantly increased proportion of rapid acetylators was found in contact-allergic patients. This may have 2 possible implications: acetylation may enhance contact sensitization; or NAT2 status may be a genetic marker for contact sensitizability.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D001191 Arylamine N-Acetyltransferase An enzyme that catalyzes the transfer of acetyl groups from ACETYL-COA to arylamines. It can also catalyze acetyl transfer between arylamines without COENZYME A and has a wide specificity for aromatic amines, including SEROTONIN. However, arylamine N-acetyltransferase should not be confused with the enzyme ARYLALKYLAMINE N-ACETYLTRANSFERASE which is also referred to as SEROTONIN ACETYLTRANSFERASE. Arylamine Acetylases,Arylamine Acetyltransferases,Acetyl-CoA Arylamine N-Acetyltransferase,Arylamine Acetylase,Acetyl CoA Arylamine N Acetyltransferase,Acetylase, Arylamine,Acetylases, Arylamine,Acetyltransferases, Arylamine,Arylamine N Acetyltransferase,Arylamine N-Acetyltransferase, Acetyl-CoA,N-Acetyltransferase, Acetyl-CoA Arylamine,N-Acetyltransferase, Arylamine
D013418 Sulfamethazine A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides. Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)-,Sulfadimidine,Sulphamethazine,Sulfadimezine,Sulphamezathine

Related Publications

A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
May 2001, Clinical pharmacology and therapeutics,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
May 2009, Archives of medical research,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
July 2018, European journal of clinical pharmacology,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
May 2009, Bioinformatics (Oxford, England),
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
March 1999, Pediatric research,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
January 2012, Hepatology international,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
October 2010, International journal of clinical pharmacology and therapeutics,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
August 1991, Biochemical pharmacology,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
January 2002, Therapie,
A Schnuch, and G A Westphal, and M M Müller, and T G Schulz, and J Geier, and J Brasch, and H F Merk, and Y Kawakubo, and G Richter, and P Koch, and T Fuchs, and T Gutgesell, and K Reich, and M Gebhardt, and D Becker, and J Grabbe, and C Szliska, and W Aberer, and E Hallier
October 2010, Toxicology mechanisms and methods,
Copied contents to your clipboard!